Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

BGB-11417: 123 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
123
Total FAERS Reports
40 (32.5%)
Deaths Reported
95
Hospitalizations
123
As Primary/Secondary Suspect
24
Life-Threatening

First Report: 20210625 · Latest Report: 20230917

What Are the Most Common BGB-11417 Side Effects?

#1 Most Reported
Febrile neutropenia
16 reports (13.0%)
#2 Most Reported
Neutropenic sepsis
10 reports (8.1%)
#3 Most Reported
Death
10 reports (8.1%)

All BGB-11417 Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Febrile neutropenia 16 13.0% 1 16
Death 10 8.1% 10 1
Neutropenic sepsis 10 8.1% 3 10
Acute myeloid leukaemia 9 7.3% 9 7
Pneumonia 7 5.7% 5 4
Off label use 6 4.9% 3 6
Covid-19 5 4.1% 0 5
Pyrexia 5 4.1% 2 3
Sepsis 5 4.1% 4 4

Who Reports BGB-11417 Side Effects? Age & Gender Data

Gender: 38.8% female, 61.2% male. Average age: 69.2 years. Most reports from: AU. View detailed demographics →

Is BGB-11417 Getting Safer? Reports by Year

YearReportsDeathsHosp.
2021 29 6 23
2022 70 30 57
2023 17 4 14

View full timeline →

What Is BGB-11417 Used For?

IndicationReports
Acute myeloid leukaemia 95
Myelodysplastic syndrome 19
Product used for unknown indication 7

BGB-11417 vs Alternatives: Which Is Safer?

BGB-11417 vs BICALUTAMIDE BGB-11417 vs BICTEGRAVIR BGB-11417 vs BICTEGRAVIR\EMTRICITABINE\TENOFOVIR ALAFENAMIDE BGB-11417 vs BIFIDOBACTERIUM LONGUM BGB-11417 vs BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS BGB-11417 vs BILASTINE BGB-11417 vs BIMATOPROST BGB-11417 vs BIMATOPROST\TIMOLOL BGB-11417 vs BIMEKIZUMAB BGB-11417 vs BIMEKIZUMAB-BKZX

Official FDA Label for BGB-11417

Official prescribing information from the FDA-approved drug label.